Biotech Values

[ghmm]

LGND: I don't know if you caught the Oppenheimer presentation. There were a couple of interesting things (at least on the slides)
1. GSK will do (another) CLD study with Promacta (for those not familiar the prior trial was stopped because of safety). I remember at the 2010 R&D Day (for Ligand) the doc saying about why he thinks its still a good indication and how to mitigated some of the problems that caused the safety concerns.
2. GSK is initiating Phase 3 studies for Promacta in "oncology indications"
3. GSK to file NDA for Promacta in Hep C.

IMO I think the sales growth in Promacta should continue to accelerate well into next year! I suspect the dropping of the REMS should be a big plus. The fact the GSK seems still strongly pursuing other indications is an excellent sign as well!